Subcutaneous 5-Fluorouracil Study
Author Information
Author(s): M.M. Borner, J. Kneer, C. Crevoisier, K.W. Brunner, T. Cerny
Primary Institution: Institut für Medizinische Onkologie, Universitat Bern
Hypothesis
Can subcutaneous administration of 5-fluorouracil (5-FU) provide similar bioavailability and tolerability as intravenous administration?
Conclusion
Subcutaneous 5-FU has almost complete bioavailability and is well tolerated.
Supporting Evidence
- Subcutaneous 5-FU showed a mean bioavailability of 0.89.
- Patients tolerated the subcutaneous infusion without local side effects.
- Three patients received a prolonged 24-hour subcutaneous infusion with comparable plasma levels to intravenous infusion.
Takeaway
This study tested a new way to give cancer medicine that might be easier and safer for patients. It found that the new method works almost as well as the old one.
Methodology
Eleven patients with advanced cancer received 250 mg of 5-FU either intravenously or subcutaneously, and their blood was sampled to measure drug levels.
Limitations
The study had a small sample size and some patients' data were not included due to processing errors.
Participant Demographics
Patients included both men and women aged 41 to 70 with various types of advanced cancer.
Want to read the original?
Access the complete publication on the publisher's website